Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer
Emmanuel S. Antonarakis,
Scott T. Tagawa,
Giuseppe Galletti,
Daniel Worroll,
Karla Ballman,
Marie Vanhuyse,
Guru Sonpavde,
Scott North,
Costantine Albany,
Che-Kai Tsao,
John Stewart,
Atef Zaher,
Ted Szatrowski,
Wei Zhou,
Ada Gjyrezi,
Shinsuke Tasaki,
Luigi Portella,
Yang Bai,
Timothy B. Lannin,
Shalu Suri,
Conor N. Gruber,
Erica D. Pratt,
Brian J. Kirby,
Mario A. Eisenberger,
David M. Nanus,
Fred Saad,
Paraskevi Giannakakou January 2017
Assistant Professor of Biomedical Engineering